Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.

L, Kappos; RJ, Fox; M, Burcklen; MS, Freedman; EK, Havrdová; B, Hennessy; R, Hohlfeld; F, Lublin; X, Montalban; C, Pozzilli; T, Scherz; D, D'Ambrosio; P, Linscheid; A, Vaclavkova; M, Pirozek-Lawniczek; H, Kracker; T, Sprenger

doi:10.1001/jamaneurol.2021.0405

Public

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.

Shared by NobleBlocks on May 1, 2021 • 12:00 AM UTC

Authors:

Kappos L

Fox RJ

Burcklen M

Abstract

<h4>Importance</h4>To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS).<h4>Objective</h4>To compare the efficacy of ponesimod, a select...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!